Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases (RACOST)
A RAndomized Trial Comparing COnventional With STereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases (RACOST-trial)
調査の概要
詳細な説明
Study population: patients with painful spinal metastases from solid tumors without spinal cord compression or cord instability.
Objective: This study will test the hypothesis that stereotactic radiotherapy gives a better and longer lasting reduction of pain, local control and therewith a better quality of life. This in order to optimize and to individualize the treatment options for the patient.
Study design: Complaints due to pain will be analysed using the validated Dutch Brief Pain Inventory (BPI) and side-effects will be recorded using the Common Toxicity Criteria for Adverse Events (CTCAE). In addition to this the quality of life will be analysed using the EORTC QOL-C15-PAL and EORTC QLQ-BM22 questionnaires. For analysis of cost-effectiveness the EQ-5D will be used.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Arnhem、オランダ、6815 AD
- Radiotherapiegroep Arnhem
-
Den Haag、オランダ
- Medisch Centrum Haaglanden
-
Deventer、オランダ、7416 SE
- Radiotherapiegroep Deventer
-
Maastricht、オランダ、6229 ET
- Maastro Clinic
-
Nijmegen、オランダ
- Radboudumc Nijmegen
-
Zwolle、オランダ、8025 AB
- Isala
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- solid tumor with radiological diagnosis of spinal metastases
- pain score minimum 2 on 11-point scale
- maximum of 2 consecutive or noncontiguous spinal vertebra involved by tumor at current level of interest
- No or mild neurological signs (radiculopathy, dermatomal sensory change and muscle strength of involved extremity)
- Karnofsky performance ≥60
- WHO ≤2
- life expectancy > 6 weeks
- age ≥18
- non-pregnant, non-lactating female patients
Exclusion Criteria:
- history of previous radiotherapy to the spine at current level of interest
- spinal instability or neurological deficit
- pathological fracture or impending fracture needing fixation
- prior surgery to the spine at current level of interest
- clinical signs of spinal cord compression or severe neurological deficits
- patients with a pacemaker such that MRI cannot be performed or the treatment cannot be delivered safely
- patients unable to undergo MRI
- earlier nuclear medicine treatment
- pregnancy
- altered mental status that would prohibit the understanding and giving of informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm 1
Conventional radiotherapy, 1x8Gy
|
1x8Gy
|
|
実験的:Arm 2
Stereotactic radiotherapy, 1x20Gy
|
1x20Gy or equivalent dose fractionation schedule
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pain reduction measured by the Dutch Brief Pain Inventory (BPI) questionnaire
時間枠:At six weeks since baseline
|
Pain is self-reported and measured by the validated Dutch Brief Pain Inventory (BPI) questionnaire
|
At six weeks since baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comparison of time to pain response
時間枠:pain response is calculated from the date of randomization at day 0-14, week 4, 6, and month 2, 3, 4, 6, 9, and 12
|
Pain is self-reported and measured by the validated Dutch Brief Pain Inventory (BPI) questionnaire
|
pain response is calculated from the date of randomization at day 0-14, week 4, 6, and month 2, 3, 4, 6, 9, and 12
|
|
Duration of pain relief
時間枠:Pain relief is calculated from the date of randomization at day 0-14, week 4, 6, and month 2, 3, 4, 6, 9, and 12
|
Pain is self-reported and measured by the validated Dutch Brief Pain Inventory (BPI) questionnaire
|
Pain relief is calculated from the date of randomization at day 0-14, week 4, 6, and month 2, 3, 4, 6, 9, and 12
|
|
Quality of life
時間枠:Quality of life is calculated from the date of randomization at day 0, 7, 14, week 4, 6, and month 2, 3, 4, 6, 9, and 12
|
EORTC QOL-C15-PAL and EORTC QLQ-BM22 questionnaires
|
Quality of life is calculated from the date of randomization at day 0, 7, 14, week 4, 6, and month 2, 3, 4, 6, 9, and 12
|
|
Toxicity measured by CTCAE 4.0 questionnaire
時間枠:up to months 12
|
Toxicity measuredCTCAE 4.0 questionnaire
|
up to months 12
|
協力者と研究者
捜査官
- 主任研究者:P Braam, MD、Radboudumc Nijmegen
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
脊髄転移の臨床試験
-
Memorial Sloan Kettering Cancer CenterUniversity of Pisa; University of California, San Francisco; The Champalimaud Centre, Lisbon,...積極的、募集していないメラノーマ | 肉腫 | 卵巣がん | 骨 | 軟部組織 | リンパ節 | CNS-Spinal CD/MEMBR、NOSアメリカ, イタリア, ポルトガル
conventional radiotherapyの臨床試験
-
Ming-Yuan Chen募集